Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

The Swedish national guidelines for treatment of acute myeloid leukemia (AML) recommend analysis measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in bone marrow the routine clinical setting. AML registry contains such MRD data patients diagnosed 2011-2019. Of 327 with (non-APL) MRD-results reported complete remission after two courses intensive chemotherapy 229 were MRD-negative (70%), as defined <0.1% cells leukemia-associated immunophenotype marrow. to clinicians real time. Multivariate statistical adjusted known established risk factors did not indicate an association between MFC-MRD and overall survival (HR: 1.00 [95% CI 0.61, 1.63]) a median follow-up 2.7?years. Knowledge importance status individualized decisions could have ameliorated effects independent prognostic factor survival.